Recombinant Human IL-17A

Item number: EPT053
Availability: In Stock
$99.00
$99.00
Please hurry! Only 100 left in stock

Documents

Size: 10ug
Subtotal: $99.00
10 customers are viewing this product

Customized & fast shipping

Terms and Conditions

Recombinant Human IL-17A

Recombinant Human IL-17A

$99.00

Recombinant Human IL-17A

$99.00
Size: 10ug
Description
Recombinant Human Interleukin-17A is produced by our E.coli expression system and the target gene encoding Gly24-Ala155 is expressed.
Accession
Q16552
Molecular weight
15.26 KDa
Apparent molecular weight
16 KDa, reducing conditions
Other names
Interleukin-17A; IL-17; IL-17A; Cytotoxic T-Lymphocyte-Associated Antigen 8; CTLA-8; IL17A; CTLA8; IL17
Purity
Greater than 95% as determined by reducing SDS-PAGE.
Endotoxin
Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Biological activity
Immobilized Human IL-17A(Cat#C021) at 2μg/ml (100 μl/well) can bind Anti-Human IL-17A mAb(Cat#NC012).The ED50 of Anti-Human IL-17A mAb(Cat#NC012) is 0.185 ug/ml.
Redissolve
Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage
Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Delivery condition
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Interleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. As IL-17 shares properties with IL-1 and TNF-alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis, and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation.

Related Products

Recently Viewed Products